- ISIN
- US92764N1028
- CUSIP
- 92764N102
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Oct 11, 2019
Highlights
- Market Cap
- $1.41B
- Enterprise Value
- $1.22B
- EPS (TTM)
- -$3.14
- Total Revenue (TTM)
- $65.50M
- Gross Profit (TTM)
- $183.11M
- EBITDA (TTM)
- -$448.10M
- Year Range
- $4.16 - $11.66
- Target Price
- $21.29
- ROA (TTM)
- -43.17%
- ROE (TTM)
- -54.47%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
VIR Performance Chart
Vir Biotechnology, Inc. (VIR) is up 58.7% since the beginning of the year. At $10 per share, VIR is trading 17.9% below its 52-week high of $12. Investors who bought $1,000 worth of VIR shares 5 years ago would now be looking at an investment worth $203.
Loading charts...
Returns By Period
Vir Biotechnology, Inc. (VIR) has returned 58.71% so far this year and 82.98% over the past 12 months.
Vir Biotechnology, Inc.
- 1D
- 4.48%
- 1M
- 4.13%
- YTD
- 58.71%
- 6M
- 59.23%
- 1Y
- 82.98%
- 3Y*
- -26.96%
- 5Y*
- -27.29%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
VIR Monthly Returns History
Based on dividend-adjusted daily data since Oct 11, 2019, VIR's average daily return is +0.14%, while the average monthly return is +2.12%. At this rate, an investment would double in approximately 2.8 years.
Historically, 44% of months were positive and 56% were negative. The best month was Jan 2021 with a return of +141.0%, while the worst month was Jul 2023 at -42.6%. The longest winning streak lasted 3 consecutive months, and the longest losing streak was 5 months.
On a daily basis, VIR closed higher 48% of trading days. The best single day was Jan 26, 2021 with a return of +74.3%, while the worst single day was Jul 20, 2023 at -44.9%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 23.38% | 22.18% | -1.43% | 14.01% | -6.61% | 0.31% | 58.71% | ||||||
| 2025 | 41.69% | -19.33% | -22.77% | -5.56% | -19.28% | 2.02% | 0.60% | -2.56% | 15.59% | 4.38% | 7.72% | -6.07% | -17.85% |
| 2024 | -6.56% | 19.57% | -9.88% | -16.49% | 21.39% | -13.34% | 14.16% | -18.70% | -9.32% | -0.00% | 6.28% | -7.79% | -27.04% |
| 2023 | 16.75% | -22.84% | 2.06% | 8.08% | 6.04% | -8.02% | -42.60% | -10.09% | -25.99% | -15.37% | 19.67% | 6.01% | -60.25% |
| 2022 | -18.01% | -26.62% | 2.10% | -20.88% | 26.83% | -1.32% | 9.19% | -14.60% | -18.82% | 14.00% | 28.39% | -10.31% | -39.55% |
| 2021 | 141.00% | -2.96% | -18.14% | -6.89% | -12.21% | 12.81% | -24.60% | 44.57% | -15.56% | -13.30% | 25.68% | -11.70% | 56.35% |
Benchmark Metrics
Vir Biotechnology, Inc. has an annualized alpha of 26.08%, beta of 0.72, and R2 of 0.02 versus S&P 500 Index. Calculated based on daily prices since October 11, 2019.
- This stock participated in 90.63% of S&P 500 Index downside but only 20.18% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.02 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 26.08%
- Beta
- 0.72
- R²
- 0.02
- Upside Capture
- 20.18%
- Downside Capture
- 90.63%
Return for Risk
Risk / Return Rank
VIR ranks 78 for risk / return — better than 78% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Vir Biotechnology, Inc. (VIR) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| VIR | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.83 | ||
| Sortino ratioReturn per unit of downside risk | -0.66 | ||
| Omega ratioGain probability vs. loss probability | 1.24 | 1.37 | -0.13 |
| Calmar ratioReturn relative to maximum drawdown | 3.00 | 2.78 | +0.21 |
| Martin ratioReturn relative to average drawdown | 6.84 | 12.44 | -5.59 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Vir Biotechnology, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Vir Biotechnology, Inc. was 94.85%, occurring on Aug 11, 2025. The portfolio has not yet recovered.
The current Vir Biotechnology, Inc. drawdown is 88.48%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2025 bear market2025 | -94.85%Aug 2025 | 4y 6mo | — | 5y 4moJan 2021 - now |
2020 bear market2020 | -57.62%Nov 2020 | 8mo 15d | 2mo 18d | 11mo 3dFeb 2020 - Jan 2021 |
COVID crash2020 | -38.94%Feb 2020 | 18d | 5d | 23dFeb 2020 - Feb 2020 |
2019 bear market2019 | -26.75%Nov 2019 | 1mo 16d | 1mo 21d | 3mo 7dOct 2019 - Jan 2020 |
2020 correction2020 | -13.99%Jan 2020 | 0s | 3d | 3dJan 2020 - Jan 2020 |
Drawdown Indicators
| VIR | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -94.85% | -56.78% | -38.07% |
Max Drawdown (1Y)Largest decline over 1 year | -27.82% | -9.10% | -18.72% |
Max Drawdown (3Y)Largest decline over 3 years | -82.86% | -18.90% | -63.96% |
Max Drawdown (5Y)Largest decline over 5 years | -92.15% | -25.43% | -66.72% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -88.48% | -1.80% | -86.68% |
Average DrawdownAverage peak-to-trough decline | -67.81% | -10.71% | -57.10% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 12.17% | 2.03% | +10.14% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Vir Biotechnology, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Vir Biotechnology, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for VIR relative to other companies in the Biotechnology industry. Currently, VIR has a P/S ratio of 20.6. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for VIR in comparison with other companies in the Biotechnology industry. Currently, VIR has a P/B value of 1.7. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with VIR
Add Vir Biotechnology, Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with VIR